IL126314A0 - Monoclonal specific antibodies - Google Patents

Monoclonal specific antibodies

Info

Publication number
IL126314A0
IL126314A0 IL12631497A IL12631497A IL126314A0 IL 126314 A0 IL126314 A0 IL 126314A0 IL 12631497 A IL12631497 A IL 12631497A IL 12631497 A IL12631497 A IL 12631497A IL 126314 A0 IL126314 A0 IL 126314A0
Authority
IL
Israel
Prior art keywords
psma
relates
antibodies
psm
specific antibodies
Prior art date
Application number
IL12631497A
Other versions
IL126314A (en
Original Assignee
Pacific Northwest Cancer Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24490004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL126314(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pacific Northwest Cancer Found filed Critical Pacific Northwest Cancer Found
Publication of IL126314A0 publication Critical patent/IL126314A0/en
Priority to IL15579303A priority Critical patent/IL155793A0/en
Publication of IL126314A publication Critical patent/IL126314A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, it relates to three monoclonal antibodies reactive with PSMA expressed on the cell surface and in sera of prostate cancer patients. Additionally, the present invention relates to a novel protein variant (PSM') of PSMA detected by an antibody of the invention. The hydrolase activity of PSMA and PSM' allows the use of an immunoenzymatic assay for their detection.
IL12631497A 1996-03-25 1997-03-25 Monoclonal antibodies having an antigen binding region specific for the extracellular domain of prostate specific membrane antigen (psma) IL126314A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL15579303A IL155793A0 (en) 1996-03-25 2003-05-06 Monoclonal antibodies having an antigen binding region specific for the extracellular domain of prostrate specific membrane antigen (psma)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62139996A 1996-03-25 1996-03-25
PCT/US1997/005214 WO1997035616A1 (en) 1996-03-25 1997-03-25 Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen

Publications (2)

Publication Number Publication Date
IL126314A0 true IL126314A0 (en) 1999-05-09
IL126314A IL126314A (en) 2003-07-31

Family

ID=24490004

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12631497A IL126314A (en) 1996-03-25 1997-03-25 Monoclonal antibodies having an antigen binding region specific for the extracellular domain of prostate specific membrane antigen (psma)

Country Status (10)

Country Link
EP (1) EP0914155B1 (en)
JP (1) JP4295826B2 (en)
AT (1) ATE318147T1 (en)
AU (1) AU725583B2 (en)
CA (1) CA2250141C (en)
DE (1) DE69735294T2 (en)
DK (1) DK0914155T3 (en)
ES (1) ES2260788T3 (en)
IL (1) IL126314A (en)
WO (1) WO1997035616A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953668B1 (en) 1992-11-05 2005-10-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
US7070782B1 (en) 1992-11-05 2006-07-04 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US6569432B1 (en) 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US7037647B1 (en) 1995-02-24 2006-05-02 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6150508A (en) * 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
GB2328871A (en) * 1997-09-05 1999-03-10 Merck & Co Inc Compositions for inhibiting platelet aggregation
AU3305699A (en) * 1998-02-26 1999-09-15 Beckman Coulter, Inc. Prostate-specific membrane antigens and methods of making and using
IL139699A0 (en) * 1998-06-01 2002-02-10 Urogenesys Inc Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
SE9900495D0 (en) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
WO2000050457A1 (en) * 1999-02-22 2000-08-31 Beckman Coulter, Inc. Prostate-specific membrane antigens and methods of making and using
CN100400547C (en) * 1999-07-29 2008-07-09 米德列斯公司 Human monoclonal antibodies to prostate specific membrane antigen
EP1710256A1 (en) * 1999-07-29 2006-10-11 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen
FR2797743B1 (en) * 1999-08-23 2003-08-08 Urogene PROSTATIC CELL LINE AND ITS USE FOR OBTAINING AN ESTABLISHED PROSTATIC TUMOR IN ANIMALS
AU7351800A (en) * 1999-09-13 2001-04-17 Neil H. Bander A method for isolation of prostatic epithelial cells from semen
JP4838436B2 (en) * 2001-04-04 2011-12-14 積水メディカル株式会社 Anti-human hepatic triglyceride lipase antibody
WO2002098897A2 (en) 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
AU2002305767B2 (en) 2001-09-20 2008-04-10 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for PSMA
US20040161776A1 (en) * 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP2360169B1 (en) 2001-10-23 2015-10-14 Psma Development Company, L.L.C. PSMA antibodies
DE60323677D1 (en) 2003-01-10 2008-10-30 Millennium Pharm Inc METHOD FOR DETERMINING THE REPRODUCTION OF PROSTATE CANCER
NZ560414A (en) 2005-02-18 2011-04-29 Medarex Inc Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues
EP1726650A1 (en) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
EA016186B1 (en) 2005-09-26 2012-03-30 Медарекс, Инк. Human monoclonal antibodies to cd70 and use thereof
WO2007109321A2 (en) 2006-03-20 2007-09-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
JP5286370B2 (en) * 2008-02-29 2013-09-11 アイメック Cellular enzyme-based biosensor
PT2326350E (en) 2008-09-08 2013-12-10 Psma Dev Company L L C Compounds for killing psma-expressing, taxane-resistant cancer cells
CA2752510C (en) 2009-02-17 2024-01-23 Neil Bander Methods and kits for diagnosis of cancer and prediction of therapeutic value
CA3040276A1 (en) 2009-12-02 2011-06-09 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
CN103826661B (en) 2011-04-21 2019-03-05 西雅图基因公司 New bonding agent-drug conjugate (ADC) and application thereof
UA118950C2 (en) 2011-04-22 2019-04-10 Аптево Рісьорч Енд Девелопмент Ллс Prostate-specific membrane antigen binding proteins and related compositions and methods
ES2815098T3 (en) 2013-12-23 2021-03-29 Bayer Pharma AG Linker Conjugates (ADCs) with KSP Inhibitors
CA2990076A1 (en) 2015-06-22 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
JOP20160154B1 (en) * 2015-07-31 2021-08-17 Regeneron Pharma Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof
AU2016304764C1 (en) 2015-08-07 2023-06-01 Imaginab, Inc. Antigen binding constructs to target molecules
CA2999138C (en) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Cd3 binding polypeptides
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
CN116059390A (en) 2016-03-24 2023-05-05 拜耳制药股份公司 Prodrugs of cytotoxic actives with enzymatically cleavable groups
CA3027445A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
CN110312534B (en) 2016-12-21 2023-04-04 拜耳制药股份公司 Antibody-drug-conjugates (ADC) with enzymatically cleavable groups
CN110312533B (en) 2016-12-21 2023-11-03 拜耳公司 Prodrugs of cytotoxic active agents having enzymatically cleavable groups
EP3558387B1 (en) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (adcs) having ksp inhibitors
AU2019231205A1 (en) 2018-03-06 2020-09-24 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof
WO2019245991A1 (en) * 2018-06-18 2019-12-26 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
PT3830132T (en) 2018-07-31 2023-01-05 Heidelberg Pharma Res Gmbh Humanized antibodies against psma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4204642B2 (en) * 1992-11-05 2009-01-07 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ Prostate-specific membrane antigen
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US7037647B1 (en) * 1995-02-24 2006-05-02 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof

Also Published As

Publication number Publication date
CA2250141A1 (en) 1997-10-02
AU2555297A (en) 1997-10-17
DE69735294T2 (en) 2006-09-21
EP0914155A1 (en) 1999-05-12
JP4295826B2 (en) 2009-07-15
JP2001503601A (en) 2001-03-21
WO1997035616A1 (en) 1997-10-02
AU725583B2 (en) 2000-10-12
DE69735294D1 (en) 2006-04-27
CA2250141C (en) 2008-07-29
ES2260788T3 (en) 2006-11-01
IL126314A (en) 2003-07-31
EP0914155A4 (en) 2001-05-16
EP0914155B1 (en) 2006-02-22
DK0914155T3 (en) 2006-06-26
ATE318147T1 (en) 2006-03-15

Similar Documents

Publication Publication Date Title
IL126314A0 (en) Monoclonal specific antibodies
IL138497A0 (en) Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
NZ337413A (en) Antibodies that bind to Prostate Stem Cell Antigen (PSCA) to treat prostate cancer.
AU733544C (en) Treatment and diagnosis of cancer
ES2293973T3 (en) ANTIBODIES ANTI-CCR2 HUMANIZED AND METHODS OF USE OF THE SAME.
ATE121130T1 (en) MONOCLONAL ANTIBODIES SPECIFICALLY AGAINST THE FUNCTIONAL ADHESION AREA OF THE SURFACE PROTEIN OF A PHAGOCYTE CELL.
WO1994016094A3 (en) Recombinant anti-vla4 antibody molecules
IL148113A0 (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
NZ288235A (en) Monoclonal antibody directed against the receptor tyrosine kinase flt4 and use in diagnosis and therapy
IL116617A0 (en) Monoclonal antibodies specific for advanced glycosylation endproducts in biological samples
HK1080091A1 (en) Immunoassays for specific determination of scca isoforms
NZ305083A (en) Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response
CY1109097T1 (en) VE-CANADIN ANTIBODIES COMPETITORS WITHOUT NEGATIVE EFFECTS ON VASCULAR TRANSFER
EP0974841A3 (en) Suppression of interference in immunoassays using substances derived from the framework regions of antibodies
WO1995024481A3 (en) Humanized monoclonal antibodies against human interleukin-4
EP0563244A4 (en) Human phospholipase activating protein and methods for diagnosis of rheumatoid arthritis
TW288020B (en) Monoclonal antibodies specific to methamphetamine, hybridoma producing the antibodies, kits containing the antibodies and uses thereof
ATE343596T1 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST ISLAND CELL ANTIGENS IA-2
ZA200200730B (en) Human monoclonal antibodies to prostate specific membrane antigen.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired